RGEN
Price
$166.91Alerts
Change
-$5.72 (-3.31%)
Updated
Nov 12, 11:40 AM (EDT)
Capitalization
9.79B
104 days until earnings call
Intraday BUY SELL Signals
STVN
Price
$13.91Alerts
Change
+$0.38 (+2.81%)
Updated
Nov 11 closing price
Capitalization
3.71B
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGEN vs STVN

RGEN vs STVN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RGEN vs. STVN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Hold and STVN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RGEN with price predictions
Nov 11, 2026

RGEN in downward trend: price dove below 50-day moving average on November 10, 2026

RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 71 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for STVN with price predictions
Nov 11, 2026

STVN's Stochastic Oscillator is staying in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +3.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 239 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

STVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STVN as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for STVN turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for STVN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.391) is normal, around the industry mean (4.964). P/E Ratio (27.694) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. STVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RGEN: Fundamental Ratings
RGEN
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
88
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RGENSTVN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (RGEN: $172.62 vs. STVN: $13.91)
Brand notoriety: RGEN and STVN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: RGEN: 76% vs. STVN: 152%
Market capitalization -- RGEN: $9.79B vs. STVN: $3.71B
RGEN [@Pharmaceuticals: Other] is valued at $9.79B. STVN’s [@Pharmaceuticals: Other] market capitalization is $3.71B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGEN’s FA Score shows that 0 FA rating(s) are green while STVN’s FA Score has 0 green FA rating(s).

  • RGEN’s FA Score: 0 green, 5 red.
  • STVN’s FA Score: 0 green, 5 red.
According to our system of comparison, RGEN is a better buy in the long-term than STVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGEN’s TA Score shows that 2 TA indicator(s) are bullish while STVN’s TA Score has 4 bullish TA indicator(s).

  • RGEN’s TA Score: 2 bullish, 6 bearish.
  • STVN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, STVN is a better buy in the short-term than RGEN.

Price Growth

RGEN (@Pharmaceuticals: Other) experienced а -3.13% price change this week, while STVN (@Pharmaceuticals: Other) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.09%. For the same industry, the average monthly price growth was +7.40%, and the average quarterly price growth was +22.84%.

Reported Earning Dates

RGEN is expected to report earnings on Feb 24, 2027.

STVN is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (+5.09% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

STVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, STVN has been loosely correlated with WST. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STVN jumps, then WST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STVN
1D Price
Change %
STVN100%
+2.81%
WST - STVN
38%
Loosely correlated
+0.08%
MTD - STVN
37%
Loosely correlated
-0.14%
RGEN - STVN
36%
Loosely correlated
-0.78%
NPCE - STVN
35%
Loosely correlated
-1.34%
BRKR - STVN
35%
Loosely correlated
+0.27%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TCHP48.290.92
+1.94%
T. Rowe Price Blue Chip Growth ETF (TCHP)
VSHY21.420.04
+0.18%
Virtus Newfleet Short Duration High Yield Bond ETF (VSHY)
TMB24.920.03
+0.10%
Thornburg Multi Sector Bond ETF (TMB)
MMAY33.33N/A
N/A
Pacer Swan SOS Moderate (May) ETF (MMAY)
NBFC49.51-0.08
-0.16%
Neuberger Flexible Credit Income ETF (NBFC)